Table 4.

Oral MOA profiles of the CRT products relative to their non-CRT comparators among oral abusers of the product category

MOA	Product Category	Weighted Abuse Prevalence*	95% CI	Relative Risk	95% CI	P
Swallowing whole	CRT	48.96	47.80–50.12	Reference
	Non-CRT	49.70	49.08–50.32	1.01	0.99–1.04	0.2734
Chewing	CRT	22.65	21.70–23.64	Reference
	Non-CRT	16.79	16.32–17.27	0.74	0.70–0.78	<0.0001
Dissolving in the mouth	CRT	7.66	7.09–8.28	Reference
	Non-CRT	6.00	5.68–6.33	0.78	0.71–0.86	<0.0001
Dissolving in liquid	CRT	2.58	2.26–2.94	Reference
	Non-CRT	2.96	2.74–3.20	1.01	0.99–1.34	0.8705

CI = confidence interval; CRT = crush-resistant tablet formulations; MOA = mode of administration.

^*The denominator is the number of abusers of the product by oral route only; the prevalence estimate is the cases per 100 oral abusers of the product category.